Fat intake and cardiovascular response

Current Hypertension Reports

Volumn 10, Issue 1, 2008, Pages 25-31

  Damjanovi, Marlen ^b   Barton, Matthias ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; NITRIC OXIDE;

ARTERIAL PRESSURE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG MECHANISM; FAT INTAKE; GLOMERULUS FILTRATION RATE; GROWTH REGULATION; HEART OUTPUT; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY TUBULE ABSORPTION; NONHUMAN; OBESITY; PATHOGENESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; VASCULAR DISEASE; VASCULAR RESISTANCE;

ANGIOTENSIN II; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DIETARY FATS; ENDOTHELIN-1; HUMANS; NITRIC OXIDE; OBESITY; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 39149096880     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0007-0     Document Type: Review

References (71)

1. Seidell JC: Obesity, insulin resistance and diabetes - a worldwide epidemic. Br J Nutr 2000, 83(Suppl 1):S5-S8.
2. Barton M, Furrer J: Cardiovascular consequences of the obesity pandemic: need for action. Expert Opin Investig Drugs 2003, 12:1757-1759.
3. Jain A: Treating obesity in individuals and populations. BMJ 2005, 331:1387-1390.
4. O'Dowd A: More than 12 million adults in England will be obese by 2010. BMJ 2006, 333:463.
5. Hamilton MT, Hamilton DG, Zderic TW: The role of low energy expenditure and sitting on obesity, metabolic syndrome, type 2 diabetes, and cardiovascular disease. Diabetes 2007, 56:2655-2667.
6. Barton M, Carmona R, Ortmann J, et al.: Obesity-associated activation of angiotensin and endothelin in the cardiovascular system. Int J Biochem Cell Biol 2003, 35:826-837
7. Bramlage P, Pittrow D, Wittchen HU, et al.: Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004, 17:904-910.
8. Messerli FH, Williams B, Ritz E: Essential hypertension. Lancet 2007, 370:591-603.
9. Carretero OA, Oparil S: Essential hypertension. Part I: definition and etiology. Circulation 2000, 101:329-335.
10. Guyton AC: Blood pressure control - special role of the kidneys and body fluids. Science 1991, 252:1813-1816.
11. Campese VM, Park J: The kidney and hypertension: over 70 years of research. J Nephrol 2006, 19:691-698.
12. Macdonald R: European GPs don't know how to deal with obesity epidemic. BMJ 2005, 330:1348.
13. Barton M, Furrer J: Cardiovascular consequences of the obesity pandemic: need for action. Expert Opin Investig Drugs 2003, 12:1757-1759.
14. Hall JE, Hildebrandt DA, Kuo J: Obesity hypertension: role of leptin and sympathetic nervous system. Am J Hypertens 2001, 14(6 Pt 2):103S-115S.
15. Hall JE, Crook ED, Jones DW, et al.: Mechanisms of obesity-associated cardiovascular and renal disease. Am J Med Sci 2002, 324:127-137.
16. Hall JE: The kidney, hypertension, and obesity. Hypertension 2003, 41(3 Pt 2):625-633.
17. Rocchini AP, Moorehead C, DeRemer S, et al.: Hyper-insulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension 1990, 15(6 Pt 2):861-866.
18. Sharma AM: Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004, 44:12-19.
19. Crowley SD, Gurley SB, Herrera MJ, et al.: Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A 2006, 103:17985-17990.
20. Rocchini AP, Key J, Bondie D, et al.: The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989, 321:580-585.
21. Rocchini AP, Katch V, Kveselis D, et al.: Insulin and renal sodium retention in obese adolescents. Hypertension 1989, 14:367-374.
22. Hall JE, Brands MW, Hildebrandt DA, Mizelle HL: Obesity-associated hypertension. Hyperinsulinemia and renal mechanisms. Hypertension 1992, 19(1 Suppl):I45-I55.
23. Sechi LA: Mechanisms of insulin resistance in rat models of hypertension and their relationships with salt sensitivity. J Hypertens 1999, 17:1229-1237.
24. Barton M, Carmona R, Morawietz H, et al.: Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension 2000, 35(1 Pt 2):329-336.
25. Traupe T, Lang M, Goettsch W, et al.: Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 2002, 20:2239-2245.
26. Traupe T, D'Uscio LV, Muenter K, et al.: Effects of obesity on endothelium-dependent reactivity during acute nitric oxide synthase inhibition: modulatory role of endothelin. Clin Sci (Lond) 2002, 103(Suppl 48):13S-15S.
27. Mundy AL, Haas E, Bhattacharya I, et al.: Endothelin stimulates vascular hydroxyl radical formation: effect of obesity. Am J Physiol Regul Integr Comp Physiol 2007, Epub ahead of print. doi:10.1152/ajpregu.00295.2007.
28. Mundy AL, Haas E, Bhattacharya I, et al.: Fat intake modifies vascular responsiveness and receptor expression of vasoconstrictors: implications for diet-induced obesity. Cardiovasc Res 2007, 73:368-375.
29. Lago RM, Singh PP, Nesto RW: Diabetes and hypertension. Nat Clin Pract Endocrinol Metab 2007, 3:667.
30. Kramer H: Obesity and chronic kidney disease. Contrib Nephrol 2006, 151:1-18.
31. Weir MR, Dzau VJ: The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999, 12(12 Pt 3):205S-213S.
32. Sharma AM, Engeli S: The role of renin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr 2006, 1:29-35.
33. Mehta PK, Griendling KK: Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007, 292:C82-97.
34. Nickenig G, Ostergren J, Struijker-Boudier H: Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers. J Renin Angiotensin Aldosterone Syst 2006, 7(Suppl 1):S1-S7.
35. Oro C, Qian H, Thomas WG: Type 1 angiotensin receptor pharmacology: signaling beyond G proteins. Pharmacol Ther 2007, 113:210-226.
36. Stepp DW, Boesen EI, Sullivan JC, et al.: Obesity augments vasoconstrictor reactivity to angiotensin II in the renal circulation of the Zucker rat. Am J Physiol Heart Circ Physiol 2007, 293:H2537-H2542.
37. Siddiqui AH, Hussain T: Enhanced AT1 receptor-mediated vasocontractile response to ANG II in endothelium-denuded aorta of obese Zucker rats. Am J Physiol Heart Circ Physiol 2007, 292:H1722-H1727.
38. Kedzierski RM, Yanagisawa M: Endothelin system: the double-edged sword in health and disease. Annu Rev Pharmacol Toxicol 2001, 41:851-876.
39. Kawaguchi H, Sawa H, Yasuda H: Endothelin stimulates angiotensin I to angiotensin II conversion in cultured pulmonary artery endothelial cells. J Mol Cell Cardiol 1990, 22:839-842.
40. Moroi M, Fukazawa M, Ishikawa M, et al.: Effect of endothelin on angiotensin converting enzyme activity in cultured vascular smooth muscle cells. Gen Pharmacol 1996, 27:463-465.
41. A receptors for endothelin regulation. Biochem Biophys Res Commun 1997, 238:861-865.
42. Fujisaki H, Ito H, Hirata Y, et al.: Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995, 96:1059-1065.
43. Luscher TF, Barton M: Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000, 102:2434-2440.
44. Barton M, d'Uscio LV, Shaw S, et al.: ET(A) receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998, 31(1 Pt 2):499-504.
45. Mather KJ, Mirzamohammadi B, Lteif A, et al.: Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002, 51:3517-3523.
46. Schiffrin EL: Vascular endothelin in hypertension. Vascul Pharmacol 2005, 43:19-29.
47. Cardillo C, Campia U, Iantorno M, Panza JA: Enhanced vascular activity of endogenous endothelin-1 in obese hypertensive patients. Hypertension 2004, 43:36-40.
48. da Silva AA, Kuo JJ, Tallam LS, Hall JE: Role of endothelin-1 in blood pressure regulation in a rat model of visceral obesity and hypertension. Hypertension 2004, 43:383-387.
49. Li H, Forstermann U: Nitric oxide in the pathogenesis of vascular disease. J Pathol 2000, 190:244-254.
50. Ignarro LJ, Buga GM, Wood KS, et al.: Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987, 84:9265-9269.
51. Forstermann U, Munzel T: Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006, 113:1708-1714.
52. Avogaro A, de Kreutzenberg SV: Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta 2005, 360:9-26.
53. Fulton D, Gratton JP, McCabe TJ, et al.: Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
54. Dimmeler S, Fleming I, Fisslthaler B, et al.: Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999, 399:601-605.
55. Burgoyne JR, Madhani M, Cuello F, et al.: Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 2007, 317:1393-1397.
56. Bhattacharya I, Mundy AL, Widmer CC, et al.: Regional heterogeneity of functional changes in conduit arteries after high-fat diet. Obesity 2007, In press.
57. Barton M, Cosentino F, Brandes RP, et al.: Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension 1997, 30:817-824.
58. Widmer CC, Mundy AL, Kretz M, Barton M: Marked heterogeneity of endothelin-mediated contractility and contraction dynamics in mouse renal and femoral arteries. Exp Biol Med (Maywood) 2006, 231:777-781.
59. Nagao T, Illiano S, Vanhoutte PM: Heterogeneous distribution of endothelium-dependent relaxations resistant to NG-nitro-L-arginine in rats. Am J Physiol 1992, 263(4 Pt 2): H1090-H1094.
60. Brandes RP, Schmitz-Winnenthal FH, Feletou M, et al.: An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci U S A 2000, 97:9747-9752.
61. Shi Y, Ku DD, Man RY, Vanhoutte PM: Augmented endothelium-derived hyperpolarizing factor-mediated relaxations attenuate endothelial dysfunction in femoral and mesenteric, but not in carotid arteries from type I diabetic rats. J Pharmacol Exp Ther 2006, 318:276-281.
62. Taniyama Y, Griendling KK: Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension 2003, 42:1075-1081.
63. Touyz RM, Tabet F, Schiffrin EL: Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 2003, 30:860-866.
64. Matoba T, Shimokawa H, Nakashima M, et al.: Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in mice. J Clin Invest 2000, 106:1521-1530.
65. Diep QN, Amiri F, Touyz RM, et al.: PPARalpha activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension 2002, 40:866-871.
66. Furukawa S, Fujita T, Shimabukuro M, et al.: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114:1752-1761.
67. Noronha BT, Li JM, Wheatcroft SB, et al.: Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes 2005, 54:1082-1089.
68. Li L, Fink GD, Watts SW, et al.: Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation 2003, 107:1053-1058.
69. Wedgwood S, Black SM: Endothelin-1 decreases endothelial NOS expression and activity through ETA receptor-mediated generation of hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 2005, 288:L480-487.
70. James J, Thomas P, Kerr D: Preventing childhood obesity: two year follow-up results from the Christchurch obesity prevention programme in schools (CHOPPS). BMJ 2007, 335:762.
71. Wister A, Loewen N, Kennedy-Symonds H, et al.: One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. CMAJ 2007, 177:859-865.